

PHD STUDENT FPU

EPIGENETICS AND IMMUNE DISEASE GROUP STEM CELL BIOLOGY, DEVELOPMENTAL LEUKEMIA AND IMMUNOTHERAPY GROUP (REF.: PHDFPU_EBPM_67)

The Josep Carreras Leukaemia Research Institute (IJC) is a nonprofit research institute based in Barcelona and dedicated to advancing our understanding about leukaemia and related disorders, in partnership with the University of Barcelona and University Autònoma of Barcelona. The IJC has laboratories in three clinical campuses: i) Clinic Hospital, ii) Sant Pau Hospital and iii) Germans Trias i Pujol Hospital. IJC serves as a collaborative hub for basic investigators and physicians to work together on fundamental biological and clinical aspects of leukaemia. The IJC offers an excellent work environment built around a multi-disciplinary fusion of ideas and state-of-the-art facilities.

Research Description

Dr **Esteban Ballestar's** Group at Josep Carreras Leukaemia Research Institute is looking for a candidate to carry out her/his Ph.D. thesis within the framework of a FPU (Formación de Profesorado Universitario) contract funded by the Ministry of Universities of Spain.

The topic of the proposed PhD thesis will be devoted to the main research interest of the group focused on epigenetic dysregulation in immune mediated disease. Specifically, the student will investigate how immune cell-cell communication impacts the deposition and removal of epigenetic marks in the context of inflammatory conditions, both using in vitro models and samples from patients with immune-mediated conditions.

Please also visit our group webpage:
https://www.carrerasresearch.org/en/epigenetics-and-immune-disease_124402

Dr **Pablo Menendez's** Group at Josep Carreras Leukaemia Research Institute is looking for a candidate to carry out her/his Ph.D. thesis within the framework of a FPU (Formación de Profesorado Universitario) contract funded by the Ministry of Universities of Spain.

The topic of the proposed PhD thesis will be devoted to the main research interest of the group: Stem cell biology, developmental leukemia and immunotherapy. The candidate has/her to be devoted to understand the pathogenic mechanisms underlying pediatric acute leukemia and to develop improved CAR-based adoptive cellular immunotherapies.

Please also visit our group webpage:
https://www.carrerasresearch.org/en/Stem_cells_mesenchymal_cancer_and_development

What we need

To apply for FPU grant, the candidate must fulfil some requirements:

- Bachelor's degree in Health Sciences finished after January 1, 2016.
- Student of the last course of Master degree (or recently finished), that enables to access doctoral studies.
- Average marks (out of 10) greater than 7,46 (Bachelor) and 8.36 (Master).
- Excellent score is required, as being a highly competitive call.
- Do not held a predoctoral contract for more than 24 months.

Please see FPU [call](#) for more detail and [check your eligibility in pages 6 to 8, "academic requirements"](#).

For university studies performed outside of Spain, the average marks must be computed according to the following criteria by the [Spanish Ministry of Science Innovation and Universities](#).

What we offer

FPU contract lasts 4 years and funding to cover salary is distributed as follows (euro/year):

- 16.246,02 in the first two years.
- 17.406,48 in the third year
- 21.758,10 in the fourth year.

How to apply

To apply for this opportunity, please send to jobs@carrerasresearch.org the following documentation and indicating in the subject of the message: **REF.: PHDFPU_EBPM_67**.

- Updated CV
- Academic records (degree & master) with marks and qualifications of all subjects
- Letter of motivation. Please indicate which research group are you interested in.

Applications not including the average marks will be automatically discarded.

Deadline for Applications: 6th December 2020.

Who we are?

Our mission is to carry out research into the basic, epidemiological, preventive, clinical and translational aspects of leukemia and other hematologic malignancies.

The vision of the Josep Carreras Leukaemia Research Institute is that research will identify new therapeutic targets and enable us to develop more precise and less aggressive treatments. We aspire to understand the origin and development of leukemias and other malignant hematological pathologies in order to be able to prevent them. We will work for a future in which all leukemias will be curable.

For further information, please, visit our webpage: <http://www.carrerasresearch.org/en> and the Josep Carreras nonprofit organization: <https://www.fcarreras.org/en>

The European Commission awarded the IJC the HR Excellence seal in July 2019. The IJC continues to work to maintain its policies in line with the Charter and Code principles. The HRS4R has the main objective of ensuring that research centers of excellence implement and respect the requirements of the European Charter for Researchers and the Code of Conduct for hiring researchers (from here on referred to as the Charter and Code) within their human resources policies.



This EC initiative aims to promote training, professional development, and mobility for all European scientists. The IJC supports these values and principles, which will not only serve to strengthen its internal policies but will actively stimulate excellent research and firmly situate the organization as an institution with a stimulating working environment that favors the development of its scientists.

IJC is an equal opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, and other legally protected characteristics.